表紙
市場調査レポート

二重特異性抗体治療薬市場

Bispecific Antibody Therapeutics Market (2nd Edition), 2014 - 2024

発行 ROOTS ANALYSIS 商品コード 283282
出版日 ページ情報 英文 247 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
二重特異性抗体治療薬市場 Bispecific Antibody Therapeutics Market (2nd Edition), 2014 - 2024
出版日: 2014年12月02日 ページ情報: 英文 247 Pages
概要

抗体治療薬は最も成長しているセグメントであり、米国および欧州市場ではすでに30以上の抗体治療薬が認可され利用可能となっています。

当レポートでは、現在治験中および入手可能な二重特異性抗体薬剤について調査し、市場に参入する企業の詳細、技術動向、今後10年間の市場規模予測などをまとめてお届けしています。

第1章 はじめに

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要
  • 免疫療法
  • 抗体治療薬
  • 抗体の構造
  • モノクローナル抗体対二重特異性抗体
  • 二重特異性抗体フォーマット
  • 二重特異性抗体の発展
    • 第1世代の二重特異性抗体
    • 第2世代の二重特異性抗体
  • 作用機序別二重特異性抗体の種類
  • 市場参入企業

第4章 市場概要とパイプライン

  • イントロダクション
  • 腫瘍性疾患に適応される薬剤
  • 非腫瘍性疾患に適応される薬剤
  • 前臨床における薬剤
  • パイプライン分析

第5章 現在の市場と予測

  • イントロダクション
  • 二重特異性抗体市場全体
  • 二重特異性抗体市場の発展
  • Catumaxomab / Removab
  • Blinatumomab / MT 103/ MEDI 538 / AMG 103 (Amgen / Astellas Pharma)
  • SAR156597 (Sanofi)
  • MM-111 (Merrimack Pharmaceuticals)
  • ACE910 / RG6013 (Chugai, Roche)
  • Duligotumab / MEHD7945A / RG7597 (Roche / Genentech)
  • ABT-981 (AbbVie)
  • ABT-122 (AbbVie)
  • RG7221/ RO5520985 (Roche)
  • ALX-0061 (Ablynx)
  • Ozoralizumab / ATN-103 (Ablynx)
  • その他のパイプライン薬剤

第6章 技術プラットフォーム

  • イントロダクション
  • 二重特異性抗体の製造:技術プロバイダーと利用可能技術
  • 有望技術

第7章 企業間提携;二重特異性抗体産業が成長するための柱

  • 概要
  • 最新の提携

第8章 主要企業プロファイル

  • 概要
  • AbbVie
  • Ablynx
  • Affimed
  • Amgen
  • Immunomedics
  • Merrimack Pharmaceuticals
  • Merus
  • Neovii Biotech
  • Roche
  • Sanofi
  • その他

第9章 SWOT分析

第10章 インタビュー原稿

第11章 結論

第12章 付録1;企業および組織リスト

第13章 付録2;表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RA10028

The concept of bispecific antibodies is increasingly gaining traction in the pharma industry owing to several therapeutic advantages and their potential to address challenges known with the monoclonal antibody based therapies. Bispecific antibodies are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

The market is still in its infancy. With the EMA approval for Removab in 2009 and recent filing for blinatumomab, a great deal of interest has been generated in the bispecific antibody market. The pipeline, which is rich and diverse, has drugs being developed for both oncological and non-oncological indications. These drugs are based on about 50 different technological platforms developed by companies such as Trion Pharma, Amgen, AbbVie, Ablynx, Affimed and MacroGenics amongst others. The platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system.

During the course of our research, we came across 37 molecules currently in different stages of clinical development. Over 75% of these molecules are industry sponsored and we expect around 8-9 of them to be launched by the end of this decade, providing the much needed push to this market. In addition to the clinical pipeline, we have identified over 70 molecules which are currently in preclinical / discovery phase. Technological advancements, especially in the purification of bispecific antibodies will ensure the development of products with improved safety, potency and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

Synopsis

The 2nd edition of the "Bispecific Antibody Therapeutics Market, 2014-2024" report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.

The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. These drugs are being developed for both oncological as well as non-oncological indications. The report highlights various companies which are active in the market and discusses, in detail, the underlying technologies which form the basis of many of the pipeline drugs.

Expecting more FDA and EMA approvals of bispecific antibodies in the coming years, one of the key objectives of this report has been to forecast the bispecific antibody market, currently at a nascent stage, over the course of next ten years. This is done by analysing

  • Molecules in pipeline and drugs approved for marketing across various geographical regions
  • Research programs, focused on bispecific antibody therapeutics, of global pharmaceutical companies and recently established start-ups
  • Technologies to produce bispecific antibodies
  • Development and sales potential based on target consumer segments, expected pricing and the likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs
  • Competitive landscape and inherent threats to growth in the short term and long term

The report provides short-mid term and long term market forecasts for the period 2014 - 2019 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of 11 marketed and pipeline bispecific antibodies. Owing to the niche nature of this market, with most products in the pipeline, we have provided three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1.About 50 different technology platforms have paved the way for the current pipeline of molecules. Triomab (Trion Pharma), BiTE (Amgen), DVD-Ig (AbbVie), Nanobody (Ablynx), DART (MacroGenics) and TandAb (Affimed) are some of the well-known technologies.
  • 2.Oncology currently dominates the field. About 68% of the industry sponsored molecules are being directed against oncological diseases; with almost two-third of them targeting solid tumors. Non oncological drug indications include rheumatoid arthritis, respiratory diseases and autoimmune diseases.
  • 3.Drugs are being tested for several indications. This one drug- multiple applications prospect is extremely appealing to drug manufactures as it reduces their development costs and increases chances of creation of drugs for many diseases at once.
  • 4.Interest of the large and small pharma companies is evident from the fact that about 42 instances of partnership deals have taken place in the last five years (14 in 2014 itself). There are opportunities for the large pharmaceutical companies to either in-license the technology or the product. Companies can develop innovative molecules in-house using in-licensed technology or collaborate on the development of a product already in clinical development to expand their portfolio of drugs.
  • 5.By 2024, we expect the overall market to be valued at USD 5.8 billion annually. The ongoing evolution of technology platforms and increased venture capital interest will act as strong enablers to support this rapid growth.
  • 6.Owing to the complexity of the structure of bispecific antibodies, there are abundant opportunities for contract manufacturers in this area. In particular, the purification of bispecific antibodies is a challenging task, making this field attractive for contract manufacturers and purification technology providers.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Immunotherapy: Antibody Ammunitions
  • 3.3. Antibody Based Therapeutics
    • 3.3.1. Twelve of the Approved Antibody Based Therapeutics are Non-Canonical
    • 3.3.2. Dominance of Antibody Based Therapeutics
  • 3.4. Structure of an Antibody
  • 3.5. Monoclonal Antibodies v/s. Bispecific Antibodies
  • 3.6. Bispecific Antibody Formats
  • 3.7. Evolution of Bispecific Antibodies
    • 3.7.1. First Generation Bispecific Antibodies
      • 3.7.1.1. Triomabs: Made Using Hybridomas/ Quadromas
      • 3.7.1.2. Shortcoming of First Generation Bispecific Antibodies
    • 3.7.2. Second Generation Bispecific Antibodies
      • 3.7.2.1. Tandem Single-chain Variable Fragment (scFv)
      • 3.7.2.2. Diabodies
      • 3.7.2.3. Two-in-one antibody
      • 3.7.2.4. Dual Variable Domain Antibodies (DVD-Ig)
      • 3.7.2.5. Shortcoming of Recombinant Bispecific Antibodies
  • 3.8. Types of Bispecific Antibodies by Mode of Action
    • 3.8.1. T Cell Engagement
    • 3.8.2. Pre-targeting Systems
    • 3.8.3. Ligand Neutralisation and Cross Linking of Receptors System
  • 3.9. Companies Active in the Market

4. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES

  • 4.1. Introduction
  • 4.2. Drugs Indicated for Oncological Diseases
  • 4.3. Drugs Indicated For Non-Oncological Diseases
  • 4.4. Drugs in Preclinical Trials
  • 4.5. Pipeline Analysis
    • 4.5.1. Drugs are Well Distributed in Phase I and Phase II of Clinical Trials
    • 4.5.2. Mechanism Using CD3 Antigen Recognition
    • 4.5.3. Pipeline Dominated by Drugs Indicated for Oncological Diseases
    • 4.5.4. Companies with the Most Active Pipeline

5. CURRENT MARKET AND FORECAST

  • 5.1. Introduction
    • 5.1.1. Scope and Limitations
    • 5.1.2. Assumptions for Market Forecast
  • 5.2. Overall Bispecific Antibodies Market
    • 5.2.1. Overall Bispecific Antibodies Market Forecast: Short-Midterm, 2014 -2019
    • 5.2.2. Overall Bispecific Antibodies Market Forecast: Long Term, 2019- 2024
  • 5.3. Evolution of the Bispecific Antibody Market: 2014, 2019 and 2024
  • 5.4. Catumaxomab / Removab (Neovii Biotech)
    • 5.4.1. Drug Specifications
    • 5.4.2. Structure and Mechanism of Action
    • 5.4.3. Orphan Drug Designations
    • 5.4.4. Geographical Presence
    • 5.4.5. Cost
    • 5.4.6. Manufacturing
    • 5.4.7. Current Status of Development
    • 5.4.8. Historical Sales (2011 - Q1 2013)
    • 5.4.9. Reimbursement
    • 5.4.10. Market Opportunity in Cancer Associated Malignant Ascites
    • 5.4.11. Catumaxomab / RemovabSales Forecast: Short-Mid Term, 2014 - 2019
    • 5.4.12. Catumaxomab / RemovabSales Forecast: Long Term, 2019 - 2024
  • 5.5. Blinatumomab / MT 103/ MEDI 538 / AMG 103 (Amgen / Astellas Pharma)
    • 5.5.1. Drug Specifications
    • 5.5.2. Mechanism of Action
    • 5.5.3. Amgen Driving Further Development
    • 5.5.4. Orphan Drug Designation
    • 5.5.5. Current Development Status
    • 5.5.6. Key Clinical Trial Results
    • 5.5.7. Competitive Landscape
    • 5.5.8. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Short-Mid Term, 2014 - 2019
    • 5.5.9. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Long Term, 2019 - 2024
  • 5.6. SAR156597 (Sanofi)
    • 5.6.1. Drug Specifications
    • 5.6.2. Mechanism of Action
    • 5.6.3. Orphan Drug Status
    • 5.6.4. Idiopathic Pulmonary Fibrosis: An Attractive Opportunity
    • 5.6.5. Current Status of Development
    • 5.6.6. SAR156597 Sales Forecast: Short-Mid Term, 2014 - 2019
    • 5.6.7. SAR156597 Sales Forecast: Long Term, 2019 - 2024
  • 5.7. MM-111 (Merrimack Pharmaceuticals)
    • 5.7.1. Drug Specifications
    • 5.7.2. Mechanism of Action
    • 5.7.3. Orphan Drug Designation
    • 5.7.4. Manufacturing
    • 5.7.5. Current Development Status
    • 5.7.6. Key Clinical Trial Results
    • 5.7.7. Companion Diagnostic Under Development
    • 5.7.8. MM-111 Sales Forecast: Short-Mid Term, 2014-2019
    • 5.7.9. MM-111 Sales Forecast: Long Term, 2019 - 2024
  • 5.8. ACE910 / RG6013 (Chugai, Roche)
    • 5.8.1. Drug Specifications
    • 5.8.2. Mechanism of Action
    • 5.8.3. Current Development Status
    • 5.8.4. Competiton for ACE910
    • 5.8.5. ACE910 / RG6013 Sales Forecast: Short-Mid Term, 2014 - 2019
    • 5.8.6. ACE910 / RG6013 Sales Forecast: Long Term, 2019 - 2024
  • 5.9. Duligotumab / MEHD7945A / RG7597 (Roche / Genentech)
    • 5.9.1. Drug Specifications
    • 5.9.2. Structure and Mechanism of Action
    • 5.9.3. Current Status of Development
    • 5.9.4. Key Clinical Trial Results
    • 5.9.5. Competition for Duligotumab
    • 5.9.6. Duligotumab/MEHD7945A / RG7597Sales Forecast: Long Term, 2019 - 2024
  • 5.10. ABT-981 (AbbVie)
    • 5.10.1. Drug Specifications
    • 5.10.2. Mechanism of Action
    • 5.10.3. Current Development Status
    • 5.10.4. Key Clinical Trial Results
    • 5.10.5. Competiton for ABT-981
    • 5.10.6. ABT-981 Sales Forecast: Long Term, 2019 - 2024
  • 5.11. ABT-122 (AbbVie)
    • 5.11.1. Drug Specifications
    • 5.11.2. Mechanism of Action
    • 5.11.3. Current Development Status
    • 5.11.4. Competition for ABT-122
    • 5.11.5. ABT-122 Sales Forecast: Long Term, 2019 - 2024
  • 5.12. RG7221/ RO5520985 (Roche)
    • 5.12.1. Drug Specifications
    • 5.12.2. Mechanism of Action
    • 5.12.3. Current Development Status
    • 5.12.4. Competition for RG7221
    • 5.12.5. RG7221 / RO5520985 Sales Forecast: Long Term, 2019 - 2024
  • 5.13. ALX-0061 (Ablynx)
    • 5.13.1. Drug Specifications
    • 5.13.2. Mechanism of Action
    • 5.13.3. Desirable Features of ALX-0061
    • 5.13.4. Current Status of Development
    • 5.13.5. Key Clinical Trial Results
    • 5.13.6. Competiton for ALX-0061
    • 5.13.7. Collaboration with AbbVie
    • 5.13.8. ALX-0061 Sales Forecast: Long Term, 2019 - 2024
  • 5.14. Ozoralizumab / ATN-103 (Ablynx)
    • 5.14.1. Drug Specifications
    • 5.14.2. Mechanism of Action
    • 5.14.3. Highs and Lows of Development
    • 5.14.4. CurrentStatus of Development
    • 5.14.5. Key Clinical Trial Results
    • 5.14.6. Competition for Ozoralizumab
    • 5.14.7. Ozoralizumab / ATN-103 Sales Forecast: Long Term, 2019 - 2024
  • 5.15. Profiles of Some Other Pipeline Drugs
    • 5.15.1. AFM 13 (Affimed) - Phase II Planned
      • 5.15.1.1. Drug Specifications
      • 5.15.1.2. Mechanism of Action
      • 5.15.1.3. Co-funding Agreement with the Leukemia and Lymphoma Society
      • 5.15.1.4. Current Development Status and Future Plans
      • 5.15.1.5. Competiton for AFM13
    • 5.15.2. CD20Bi / FBT-A05 / Lymphomun (Fresenius Biotech) - investigator-sponsored trials
      • 5.15.2.1. Drug Specifications and Mechanism of Action
      • 5.15.2.2. Current Development Status
    • 5.15.3. TF2 (Immunomedics) - pretargeting imaging and radioimmunotherapy agent
      • 5.15.3.1. Drug Specifications
      • 5.15.3.2. Mechanism of Action
      • 5.15.3.3. Current Development Status
    • 5.15.4. Ertumaxomab/Rexomun (Fresenius Biotech) - investigator-sponsored trials
      • 5.15.4.1. Drug Specifications
      • 5.15.4.2. Current Development Status

6. TECHNOLOGY PLATFORMS

  • 6.1. Introduction
  • 6.2. Bispecific Antibody Production: Technology Providers and Available Technologies
  • 6.3. Promising Technologies
    • 6.3.1. Triomab / Quadroma (Trion Pharma)
      • 6.3.1.1. The Technology
      • 6.3.1.2. Drugs Based on Triomab
      • 6.3.1.3. Pharmaceutical Companies Showing Interest in the Technology
    • 6.3.2. Tribody Technology (Biotecnol)
      • 6.3.2.1. The Technology
      • 6.3.2.2. Drugs Based on Tribody
      • 6.3.2.3. Pharmaceutical Companies Showing Interest in the Technology
      • 6.3.2.4. Advantages of Tribody Technology
    • 6.3.3. Bispecific T Cell Engager / BiTE (Amgen)
      • 6.3.3.1. The Technology
      • 6.3.3.2. Drugs Based on BiTE
      • 6.3.3.3. Pharmaceutical Companies Showing Interest in the Technology
      • 6.3.3.4. Advantages of BiTE Technology
    • 6.3.4. DART (MacroGenics)
      • 6.3.4.1. The Technology
      • 6.3.4.2. Drugs Based on DART
      • 6.3.4.3. Pharmaceutical Companies Showing Interest in the Technology
      • 6.3.4.4. Advantages of DART
    • 6.3.5. DuoBody (Genmab)
      • 6.3.5.1. The Technology
      • 6.3.5.2. Drugs Based on DuoBody
      • 6.3.5.3. Pharmaceutical Companies Showing Interest in the Technology
      • 6.3.5.4. Advantages of DuoBody Technology
    • 6.3.6. TandAb (Affimed)
      • 6.3.6.1. The Technology
      • 6.3.6.2. Drugs Based on TandAb
      • 6.3.6.3. Advantages of TandAb Technology
    • 6.3.7. DVD-Ig (AbbVie)
      • 6.3.7.1. The Technology
      • 6.3.7.2. Drugs Based on DVD-Ig
      • 6.3.7.3. Advantages of DVD-Ig Technology
    • 6.3.8. Nanobody (Ablynx)
      • 6.3.8.1. The Technology
      • 6.3.8.2. Drugs Based on Nanobody
      • 6.3.8.3. Pharmaceutical Companies Showing Interest in the Technology
      • 6.3.8.4. Advantages of Nanobody
    • 6.3.9. CrossMab Technology (Roche)
      • 6.3.9.1. The Technology
      • 6.3.9.2. Drugs Based on CrossMab
      • 6.3.9.3. Advantages of CrossMab
    • 6.3.10. Dock and Lock (Immunomedics)
      • 6.3.10.1. The Technology
      • 6.3.10.2. Drugs Based on DNL
      • 6.3.10.3. Advantages of DNL Technology

7. PARTNERSHIPS: BACKBONE OF THE GROWING BISPECIFIC INDUSTRY

  • 7.1. Chapter Overview
  • 7.2. Recent Partnerships
    • 7.2.1. Partnership Models
    • 7.2.2. Collaborations Amongst Stakeholders are on a Rise
    • 7.2.3. Product Development Model is the Preferred Mode of Collaboration
    • 7.2.4. Most Active Companies

8. PROFILES OF LEADING COMPANIES

  • 8.1. Chapter Overview
  • 8.2. AbbVie
    • 8.2.1. Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Technology and PipelineDrugs
      • 8.2.3.1. DVD-Ig: The Proprietary Technology
      • 8.2.3.2. Pipeline Drugs
    • 8.2.4. Other Information
  • 8.3. Ablynx
    • 8.3.1. Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Funding
    • 8.3.4. Technology and Pipeline Drugs
      • 8.3.4.1. Nanobody: The Proprietary Technology
      • 8.3.4.2. Pipeline Drugs
    • 8.3.5. Other Information
  • 8.4. Affimed
    • 8.4.1. Overview
    • 8.4.2. Funding
    • 8.4.3. Technology and Pipeline Drugs
      • 8.4.3.1. TandAb Technology
      • 8.4.3.2. Pipeline Drugs
    • 8.4.4. Other Information
  • 8.5. Amgen
    • 8.5.1. Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Technology and Pipeline Drugs
      • 8.5.3.1. BiTE: The Proprietary Technology
      • 8.5.3.2. Pipeline Drugs
    • 8.5.4. Other Information
  • 8.6. Immunomedics
    • 8.6.1. Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Technology and Pipeline Drugs
      • 8.6.3.1. DOCK-AND-LOCK (DNL): The Proprietary Technology
      • 8.6.3.2. Pipeline Drugs
  • 8.7. Merrimack Pharmaceuticals
    • 8.7.1. Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Technology and Pipeline Drugs
    • 8.7.4. Other Information
  • 8.8. Merus
    • 8.8.1. Overview
    • 8.8.2. Funding
    • 8.8.3. Technology and Pipeline Drugs
      • 8.8.3.1. Biclonics: The Proprietary Technology
      • 8.8.3.2. Pipeline Drugs
    • 8.8.4. Other Information
  • 8.9. Neovii Biotech
    • 8.9.1. Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Technologyand Pipeline Drugs
      • 8.9.3.1. Removab: The only Marketed Bispecific Antibody
    • 8.9.4. Other Information
  • 8.10. Roche
    • 8.10.1. Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Technology and Pipeline Drugs
      • 8.10.3.1. The Proprietary Technologies
      • 8.10.3.2. Pipeline Drugs
      • 8.10.3.3. Other Information
  • 8.11. Sanofi
    • 8.11.1. Overview
    • 8.11.2. Financial Performance
    • 8.11.3. Technology and Pipeline Drugs
      • 8.11.3.1. TBTI (tetravalent bispecific tandem Ig): The Proprietary Technology
      • 8.11.3.2. Pipeline Drugs
  • 8.12. Brief Company Profiles
    • 8.12.1. Baliopharm
    • 8.12.2. Bayer
    • 8.12.3. Biotecnol
    • 8.12.4. GSK
    • 8.12.5. MacroGenics
    • 8.12.6. NovImmune
    • 8.12.7. Numab
    • 8.12.8. Paktis Antibody Services GmbH
    • 8.12.9. PharmAbcine
    • 8.12.10. Sorrento Therapeutics
    • 8.12.11. Synimmune
    • 8.12.12. Xencor
    • 8.12.13. Zyngenia

9. SWOT ANALYSIS

  • 9.1. Overview
  • 9.2. Strengths
  • 9.3. Weaknesses
  • 9.4. Opportunities
  • 9.5. Threats

10. INTERVIEW TRANSCRIPTS

11. CONCLUSIONS

  • 11.1. A Budding Market Ready to Bloom
  • 11.2. With Several Advantages, Bispecific Antibodies are likely to Step Shead of Competition
  • 11.3. Improvements in Purification Systems of Bispecific Antibodies is Critical
  • 11.4. Concluding Remarks

12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS

13. APPENDIX 2: TABULATED DATA

List of Figures

  • Figure 2.1 Bispecific Antibody Therapeutics: Market Map
  • Figure 3.1 Number of Approved Non-Canonical Antibody Based Therapeutics
  • Figure 3.2 Sales of Top 10 Drugs (USD BN), 2013
  • Figure 3.3 Parts of an Antibody
  • Figure 4.1 Pipeline Drugs: By Phase of Development
  • Figure 4.2 Pipeline Drugs: By Type of Bispecific System
  • Figure 4.3 Pipeline Drugs: By Indication
  • Figure 4.4 Oncology Bispecific Drugs: By Types of Cancer
  • Figure 5.1 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.2 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.3 Evolution of Bispecific Antibodies Market: 2014, 2019 and 2024 (Base Scenario)
  • Figure 5.4 Removab Quarterly Sales, 2011-2013 (EUR MM)
  • Figure 5.5 Malignant Ascites Market Share (%): Distribution by Type of Cancer
  • Figure 5.6 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.7 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.8 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.9 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.10 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.11 SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.12 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.13 MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.14 ACE910/ RG6013 Market (USD MM), Short-MId Term Forecast: 2014 - 2019 (Base Scenario)
  • Figure 5.15 ACE910/ RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.16 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.17 ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.18 ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.19 RG7221/ RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.20 ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 5.21 Sales of Leading Anti-rheumatics Drugs, 2013(USD BN)
  • Figure 5.22 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Figure 7.1 Bispecific Antibody Partnerships by Year, Pre 2009-2014
  • Figure 7.2 Bispecific Antibody Partnerships: Distribution by Type of Partnership
  • Figure 7.3 Bispecific Antibodies Partnerships: Major Stakeholders
  • Figure 8.1 AbbVie: Financial Performance, 2012 - Q2 2014 (USD BN)
  • Figure 8.2 Amgen: Financial Performance, 2012 - Q3 2014 (USD BN)
  • Figure 8.3 Immunomedics: Financial Performance, 2012-2014 (USD MM)
  • Figure 8.4 Merrimack: Financial Performance, 2012- Q2 2014 (USD MM)
  • Figure 8.5 Roche: Financial Performance, 2012 - Q3 2014 (CHF BN)
  • Figure 8.6 Sanofi: Financial Performance, 2012 - Q3 2014 (EUR BN)
  • Figure 11.1 Bispecific Antibodies Market Forecast (USD MM): 2014, 2019, 2024

List of Tables

  • Table 3.1 Approved Antibody Based Therapeutics
  • Table 4.1 List of Bispecific Antibodies: Clinical Trials (Oncology)
  • Table 4.2 List of Bispecific Antibodies: Clinical Trials (Non-Oncology)
  • Table 4.3 List of Bispecific Antibodies: Preclinical / Discovery
  • Table 5.1 Bispecific Antibodies in Clinical Development (Phase II and Higher): Current Development Phase and Expected Launch Year
  • Table 5.2 Removab: Orphan Drug Designations
  • Table 5.3 Removab: Treatment Schedule and Cost
  • Table 5.4 Removab: Ongoing Clinical Trials
  • Table 5.5 Blinatumomab: Orphan Drug Designations
  • Table 5.6 Blinatumomab / MT 103/ MEDI 538 / AMG 103: Ongoing Clinical Trials
  • Table 5.7 Comparison of the Marketed Targeted Inhibitors for ALL
  • Table 5.8 Comparison of Blinatumomab / MT 103/ MEDI 538 / AMG 103 and SAR3419
  • Table 5.9 Drugs under Development for Idiopathic Pulmonary Fibrosis, 2014
  • Table 5.10 SAR156597: Ongoing Clinical Trials
  • Table 5.11 MM-111: Ongoing Clinical Trials
  • Table 5.12 ACE910: Ongoing Clinical Trials
  • Table 5.13 Duligotumab / MEHD7945A / RG7597: Ongoing Clinical Trials
  • Table 5.14 Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis
  • Table 5.15 ABT-981: Ongoing Clinical Trials
  • Table 5.16 ABT-122: Ongoing Clinical Trials
  • Table 5.17 RG7221: Ongoing Clinical Trials
  • Table 5.18 ALX-0061: Ongoing Clinical Trials
  • Table 5.19 ALX-0061: Competitor Drug Analysis
  • Table 5.20 Ozoralizumab / ATN-103: Ongoing Clinical Trials
  • Table 5.21 Comparison of Leading Anti-Rheumatic Drugs
  • Table 5.22 AFM13: Ongoing Clinical Trials
  • Table 5.23 Comparison of Adcetris with AFM 13
  • Table 5.24 CD20Bi: Ongoing Clinical Trials
  • Table 5.25 TF2: Ongoing Clinical Trials
  • Table 5.26 Rexomun: Ongoing Clinical Trials
  • Table 6.1 Bispecific Antibodies: List of Technology Platforms
  • Table 6.2 Drugs Based on Triomab Technology
  • Table 6.3 Drugs Based on Tribody Technology
  • Table 6.4 Drugs Based on BiTE Technology
  • Table 6.5 Drugs Based on DART
  • Table 6.6 Drugs Based on TandAb Technology
  • Table 6.7 Drugs Based on DVD-Ig Technology
  • Table 6.8 Drugs Based on Nanobody Technology
  • Table 6.9 Drugs Based on CrossMab Technology
  • Table 6.10 Drugs Based on Dock and Lock Technology
  • Table 7.1 List of Partnerships, 2000 - 2014
  • Table 8.1 AbbVie: Pipeline of Bispecific Antibodies
  • Table 8.2 Ablynx: Pipeline of Bispecific Antibodies
  • Table 8.3 Affimed: Pipeline of Bispecific Antibodies
  • Table 8.4 Amgen: Pipeline of Bispecific Antibodies
  • Table 8.5 Immunomedics: Pipeline of Bispecific Antibodies
  • Table 8.6 Merrimack Pharmaceuticals: Pipeline of Bispecific Antibodies
  • Table 8.7 Merus: Pipeline of Bispecific Antibodies
  • Table 8.8 Neovii Biotech: Pipeline of Bispecific Antibodies
  • Table 8.9 Roche: Pipeline of Bispecific Antibodies
  • Table 8.10 Sanofi: Pipeline of Bispecific Antibodies
  • Table 8.11 Baliopharm: Pipeline of Bispecific Antibodies
  • Table 8.12 Bayer: Pipeline of Bispecific Antibodies
  • Table 8.13 Biotecnol: Pipeline of Bispecific Antibodies
  • Table 8.14 GSK: Pipeline of Bispecific Antibodies
  • Table 8.15 MacroGenics: Pipeline of Bispecific Antibodies
  • Table 8.16 NovImmune: Pipeline of Bispecific Antibodies
  • Table 8.17 Numab: Pipeline of Bispecific Antibodies
  • Table 8.18 PharmAbcine: Pipeline of Bispecific Antibodies
  • Table 8.19 Sorrento Therapeutics: Pipeline of Bispecific Antibodies
  • Table 8.20 Synimmune: Pipeline of Bispecific Antibodies
  • Table 8.21 Xencor: Pipeline of Bispecific Antibodies
  • Table 8.22 Zyngenia: Pipeline of Bispecific Antibodies
  • Table 9.1 SWOT Analysis
  • Table 9.2 Contract Manufacturing Organisations with Bispecific Antibody Capabilities - Screening, Expression or Purification
  • Table 9.3 Companies Working to Develop IgG/Non-IgG Fusion Therapeutics
  • Table 13.1 Approved Non-Canonical Antibody Based Therapeutics
  • Table 13.2 Sales (USD BN) of Top 10 drugs, 2013
  • Table 13.3 Industry Sponsored Pipeline Drugs: By Phase of Development
  • Table 13.4 Industry Sponsored Pipeline Drugs: By Type of Bispecific System
  • Table 13.5 Industry Sponsored Pipeline Drugs: By Indication
  • Table 13.6 Industry Sponsored Oncology Bispecific Drugs: By Type of Cancer
  • Table 13.7 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.8 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.9 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.10 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.11 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.12 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.13 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.14 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.15 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.16 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.17 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.18 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.19 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.20 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.21 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.22 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.23 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.24 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.25 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.26 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.27 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.28 SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.29 SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.30 SAR156597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.31 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.32 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.33 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.34 MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.35 MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.36 MM-111 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.37 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Base Scenario)
  • Table 13.38 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Conservative Scenario)
  • Table 13.39 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014 - 2019 (Optimistic Scenario)
  • Table 13.40 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.41 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.42 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.43 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.44 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.45 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.46 ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.47 ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.48 ABT-981 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.49 ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.50 ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.51 ABT-122 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.52 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.53 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.54 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.55 ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.56 ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.57 ALX-0061 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.58 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Base Scenario)
  • Table 13.59 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Conservative Scenario)
  • Table 13.60 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019 - 2024 (Optimistic Scenario)
  • Table 13.61 AbbVie: Financial Performance, 2012-Q2 2014 (USD BN)
  • Table 13.62 Amgen: Financial Performance, 2012-Q3 2014 (USD BN)
  • Table 13.63 Immunomedics: Financial Performance, 2012-2014 (USD MM)
  • Table 13.64 Merrimack: Financial Performance, 2012- Q2 2014 (USD MM)
  • Table 13.65 Roche: Financial Performance, 2012-Q3 2014 (CHF BN)
  • Table 13.66 Sanofi: Financial Performance, 2012-Q3 2014 (EUR BN)

Listed Companies

The following companies have been mentioned in the report.

  • 1. AbbVie
  • 2. Abingworth Management
  • 3. Ablynx
  • 4. Active Biotech
  • 5. Adimab
  • 6. Aeris Capital
  • 7. Affimed
  • 8. Aglaia Oncology Seed Fund
  • 9. Alligator Bioscience
  • 10. Allozyne
  • 11. Alta Partners
  • 12. Ambrx
  • 13. Amgen
  • 14. Amphivena Therapeutics Inc
  • 15. ARIAD Pharmaceuticals
  • 16. Astellas Pharma
  • 17. Baliopharm
  • 18. Bay City Capital
  • 19. Bayer
  • 20. Beckman Coulter
  • 21. Beijing ABT Genetic Engineering Technology Co.
  • 22. Bicycle Therapeutics
  • 23. Biogen Idec
  • 24. Bioloine Rx
  • 25. BioMedInvest
  • 26. BioNovion
  • 27. Biotech Fund Flanders
  • 28. Biotecnol
  • 29. BMO Capital Markets Corp.
  • 30. Boehringer Ingelheim
  • 31. Bristol-Myers Squibb
  • 32. Celgene
  • 33. Cellmid
  • 34. Celonic AG
  • 35. Chiome Bioscience
  • 36. Chromacon
  • 37. Chugai
  • 38. Cipla
  • 39. Cormorant Pharmaceuticals
  • 40. Covagen
  • 41. Dow Pharma
  • 42. Dutalys
  • 43. Eddingpharm
  • 44. Eli Lilly
  • 45. EMD Serono
  • 46. Emergent Biosolutions
  • 47. Epigen Biotech
  • 48. Fabion Pharmaceuticals
  • 49. FibroGen
  • 50. Fresenius Biotech
  • 51. F-star
  • 52. Fusimab
  • 53. Ganymed Pharmaceuticals
  • 54. Genentech
  • 55. Genmab
  • 56. Gilead Sciences
  • 57. GIMV
  • 58. Glenmark Pharmaceuticals
  • 59. Glide
  • 60. Goodwin Biotechnology
  • 61. GSK
  • 62. GSK-Domantis
  • 63. Ho Research Consortium
  • 64. IBC Pharmaceuticals
  • 65. ImClone Systems (Eli Lily)
  • 66. ImmunGene
  • 67. Immunocore
  • 68. Immunomedics
  • 69. Innovent Biologics Inc.
  • 70. InterMune
  • 71. J&J
  • 72. Janssen Biotech
  • 73. Jefferies LLC
  • 74. Johnson & Johnson Development Corporation (JJDC)
  • 75. KBC
  • 76. KBI Biopharma
  • 77. Kyowa Hakko Kirin
  • 78. Leerink Partners LLC
  • 79. Life Science Partners (LSP)
  • 80. Lindis Biotech
  • 81. LSP Life Sciences Partners
  • 82. MacroGenics
  • 83. MediaPharma
  • 84. MedImmune
  • 85. Merck
  • 86. Merck Serono
  • 87. Meridian Life Science
  • 88. Merrimack Pharmaceuticals
  • 89. Merus
  • 90. Micromet
  • 91. Mitsubishi Tanabe
  • 92. Molecular Partners AG
  • 93. MorphoSys AG
  • 94. MPM Capital
  • 95. Neovii Biotech
  • 96. Novartis Option Fund
  • 97. Novartis Pharmaceuticals
  • 98. NovImmune
  • 99. Novo Nordisk A/S
  • 100. Numab
  • 101. OcellO
  • 102. OncoMed
  • 103. Orbimed
  • 104. Paktis Antibody Services GmbH
  • 105. Pfizer
  • 106. PharmAbcine
  • 107. Philogen
  • 108. ProBioGen
  • 109. Protheragen
  • 110. Receptor Logic
  • 111. Renergon Pharmaceuticals
  • 112. Roche
  • 113. Sanofi
  • 114. Sea Lane Biotechnologies
  • 115. Seattle Genetics
  • 116. Servier
  • 117. Shanghai Genomics
  • 118. Shionogi & Co.
  • 119. Sofinnova Partners
  • 120. Sorrento Therapeutics
  • 121. SR One
  • 122. Sutro Biopharma
  • 123. Symphogen
  • 124. Synergys Biotherapeutics
  • 125. Synimmune
  • 126. Takeda
  • 127. Trion Pharma
  • 128. Trout Capital LLC
  • 129. UCB-Celltech
  • 130. X-BODY Biosciences
  • 131. Xencor
  • 132. Zymeworks
  • 133. ZymoGenetics
  • 134. Zyngenia

The following organisations have been mentioned in the report.

  • 1. Australian Therapeutic Goods Administration
  • 2. Barbara Ann Karmanos Cancer Institute
  • 3. Centre René Gauducheau
  • 4. Dartmouth-Hitchcock Medical Center
  • 5. EMA
  • 6. FDA
  • 7. French National Centre for Scientific Research
  • 8. Institut National De La Santé Et De La Recherche Médicale
  • 9. Krankenhaus Nordwest
  • 10. Masonic Cancer Center, University of Minnesota
  • 11. Memorial Sloan-Kettering Cancer Institute
  • 12. Nantes University Hospital
  • 13. National Cancer Institute
  • 14. Radboud University
  • 15. Roger Williams Medical Centre
  • 16. Scott and White Hospital
  • 17. Technische Universität München
  • 18. Université de Toulouse
  • 19. University Hospital, Tuebingen
Back to Top